NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Phathom securities […]

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of G-III Apparel Group Ltd. (NASDAQ: GIII) resulting from allegations that G-III may have issued materially misleading business information to the investing public. SO WHAT: If you purchased G-III securities […]

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Provident Bancorp, Inc. (NASDAQ: PVBC) resulting from allegations that Provident may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Provident securities you may […]

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Goldman Sachs Group, Inc. (NYSE: GS) resulting from allegations that Goldman Sachs may have issued materially misleading business information to the investing public. SO WHAT: If you purchased […]

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be […]

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Surmodics securities you […]